Please use this identifier to cite or link to this item: https://ir.swu.ac.th/jspui/handle/123456789/14953
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTangjitgamol S.
dc.contributor.authorManusirivithaya S.
dc.contributor.authorChoomchuay N.
dc.contributor.authorLeelahakorn S.
dc.contributor.authorThawaramara T.
dc.contributor.authorPataradool K.
dc.contributor.authorSuekwatana P.
dc.date.accessioned2021-04-05T04:32:12Z-
dc.date.available2021-04-05T04:32:12Z-
dc.date.issued2007
dc.identifier.issn13418076
dc.identifier.other2-s2.0-33847713390
dc.identifier.urihttps://ir.swu.ac.th/jspui/handle/123456789/14953-
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-33847713390&doi=10.1111%2fj.1447-0756.2007.00509.x&partnerID=40&md5=f5ff88a7c610ad00771b079509002ba5
dc.description.abstractThe prognosis of large cell neuroendocrine carcinoma (LCNEC) of the uterine cervix is generally poor despite multimodality of treatments. We report a case of advanced stage cervical LCNEC that showed definite response to paclitaxel/carboplatin, resulting in years of survival. The patient was referred to our institution after undergoing a simple hysterectomy with bilateral salpingo-oophorectomy in her local hospital because of a ruptured metastatic ovarian mass. She declined pelvic radiation treatment, so adjuvant chemotherapy (six cycles of paclitaxel/carboplatin) was given for the residual pelvic nodal diseases. Clinical complete remission was obtained, with a disease-free period of 19 months. Systemic recurrent diseases also showed partial response to the same drug regimen for months with only minimal toxicity. However, she subsequently had progressive diseases in the liver and brain and finally died at 44 months after primary diagnosis and 19 months after recurrent diseases. © 2007 The Authors.
dc.subjectcarboplatin
dc.subjectcisplatin
dc.subjectetoposide
dc.subjectpaclitaxel
dc.subjectadrenal metastasis
dc.subjectadult
dc.subjectarticle
dc.subjectaspiration biopsy
dc.subjectbrain metastasis
dc.subjectcancer chemotherapy
dc.subjectcancer regression
dc.subjectcancer staging
dc.subjectcancer survival
dc.subjectcase report
dc.subjectclinical feature
dc.subjectcomputer assisted tomography
dc.subjectdisease free interval
dc.subjectdrug response
dc.subjectdrug substitution
dc.subjectfemale
dc.subjecthistopathology
dc.subjecthuman
dc.subjecthuman tissue
dc.subjecthysterectomy
dc.subjectlaboratory test
dc.subjectlarge cell carcinoma
dc.subjectliver metastasis
dc.subjectlymph node metastasis
dc.subjectmultiple cycle treatment
dc.subjectneuroendocrine tumor
dc.subjectovary tumor
dc.subjectrecurrent disease
dc.subjectsalpingooophorectomy
dc.subjectunspecified side effect
dc.subjectuterine cervix carcinoma
dc.subjectAdult
dc.subjectAntineoplastic Agents
dc.subjectAntineoplastic Agents, Phytogenic
dc.subjectBrain Neoplasms
dc.subjectCarboplatin
dc.subjectCarcinoma, Large Cell
dc.subjectCarcinoma, Neuroendocrine
dc.subjectChemotherapy, Adjuvant
dc.subjectCombined Modality Therapy
dc.subjectDisease Progression
dc.subjectFatal Outcome
dc.subjectFemale
dc.subjectHumans
dc.subjectLiver Neoplasms
dc.subjectNeoplasm Recurrence, Local
dc.subjectOvariectomy
dc.subjectPaclitaxel
dc.subjectUterine Cervical Neoplasms
dc.titlePaclitaxel and carboplatin for large cell neuroendocrine carcinoma of the uterine cervix
dc.typeArticle
dc.rights.holderScopus
dc.identifier.bibliograpycitationJournal of Obstetrics and Gynaecology Research. Vol 33, No.2 (2007), p.218-224
dc.identifier.doi10.1111/j.1447-0756.2007.00509.x
Appears in Collections:Scopus 1983-2021

Files in This Item:
There are no files associated with this item.


Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.